AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27486125 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 27486125 — intervention group
Group type: COMPARATOR
Intervention: NPH
Number of subjects: 0
Study 25638594 — intervention group
Group type: EXPERIMENTAL
Intervention: Antral preserving‐LSG (AP‐LSG)
Number of subjects: 113
Study 25638594 — intervention group
Group type: EXPERIMENTAL
Intervention: Antral resecting‐LSG (AR‐LSG)
Number of subjects: 113
Study 25638594 — intervention group
Group type: COMPARATOR
Intervention: Both groups (AP‐LSG and AR‐LSG)
Number of subjects: 113
Study 23190785 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib‐MenC‐TT coadministered with DTPa‐HBV‐IPV
Number of subjects: 709
Study 23190785 — intervention group
Group type: COMPARATOR
Intervention: Control vaccines (MenC‐TT coadministered with DTPa‐HBV‐IPV/Hib)
Number of subjects: 709
Study 21908754 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (CM) treatment
Number of subjects: 393
Study 21908754 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group: patients without legal problems)
Number of subjects: 393
Study 17977950 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment for 16 weeks
Number of subjects: 24
Study 17977950 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 matched control subjects)
Number of subjects: 24
Study 12914871 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (100 to 400 mg twice daily)
Number of subjects: 18942
Study 12914871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18942
Study 12914871 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 18942
Study 9888621 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (ZOP)
Number of subjects: 24
Study 9888621 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam (FLU)
Number of subjects: 24
Study 9888621 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report inventories
Number of subjects: 24
Study 8554861 — intervention group
Group type: EXPERIMENTAL
Intervention: Conductive education-based programme (CE), duration: 6 months
Number of subjects: 20
Study 8554861 — intervention group
Group type: COMPARATOR
Intervention: Traditional early intervention programmes (Control), duration: 6 months
Number of subjects: 20
Study 2922673 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth II
Number of subjects: 22
Study 2922673 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y
Number of subjects: 22
Study 65278 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbiturate
Number of subjects: 0
Study 65278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 65278 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 0
Study 65278 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 30889250 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus dry needling (DN)
Number of subjects: 62
Study 30889250 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus sham dry needling (sham DN)
Number of subjects: 62
Study 31160249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib (30 mg orally, once daily)
Number of subjects: 48
Study 31160249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 28390869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir-voxilaprevir for 8 weeks
Number of subjects: 0
Study 28390869 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir-velpatasvir for 12 weeks
Number of subjects: 0
Study 28390869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir-voxilaprevir for 8 weeks and Sofosbuvir-velpatasvir for 12 weeks in patients with HCV genotype 3 and cirrhosis
Number of subjects: 0
Study 25886377 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 755
Study 25886377 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 755
Study 25886377 — intervention group
Group type: COMPARATOR
Intervention: Usual care (GP care)
Number of subjects: 755
Study 25886377 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messaging
Number of subjects: 755
Study 23336742 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 13
Study 23336742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 13
Study 23336742 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser
Number of subjects: 13
Study 23336742 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study 21365331 — intervention group
Group type: EXPERIMENTAL
Intervention: Contasure-Needleless (C-NDL)
Number of subjects: 158
Study 21365331 — intervention group
Group type: COMPARATOR
Intervention: Transobturator Tension-free vaginal tape (TVT-O)
Number of subjects: 158
Study 19709417 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (120 mg/m2, d1) + Dacarbazine (175 mg/m2, d13)
Number of subjects: 31
Study 19709417 — intervention group
Group type: COMPARATOR
Intervention: Vincristine, Epirubicin, Cyclophosphamide (control)
Number of subjects: 31
Study 19709417 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-dacarbazine
Number of subjects: 31
Study 17598312 — intervention group
Group type: EXPERIMENTAL
Intervention: Onsite adult vaccinations (intervention group)
Number of subjects: 186
Study 17598312 — intervention group
Group type: COMPARATOR
Intervention: No vaccinations (comparison group)
Number of subjects: 186
Study 15097265 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2% (Trusopt)
Number of subjects: 43
Study 15097265 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine 0.2% (Alphagan)
Number of subjects: 43
Study 11531895 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle acupuncture (verum)
Number of subjects: 69
Study 11531895 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 69
Study 9692689 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 10 mg o.m.
Number of subjects: 674
Study 9692689 — intervention group
Group type: COMPARATOR
Intervention: antacid/alginate liquid 10 mL q.d.s.
Number of subjects: 674
Study 7836217 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 6
Study 7836217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2972158 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic ethinyl estradiol/gestoden
Number of subjects: 10
Study 2972158 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic ethinyl estradiol/desogestrel
Number of subjects: 10
Study 31766943 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with a broadband stimulus
Number of subjects: 40
Study 31766943 — intervention group
Group type: EXPERIMENTAL
Intervention: Active participation training strategy
Number of subjects: 40
Study 31766943 — intervention group
Group type: COMPARATOR
Intervention: Other training strategies (not specified)
Number of subjects: 40
Study 31823786 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilisation intervention
Number of subjects: 10112
Study 31823786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined variable of intervention/high social capital
Number of subjects: 10112
Study 31823786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10112
Study 27872061 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7667
Number of subjects: 120
Study 27872061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26621715 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 100 mg
Number of subjects: 65
Study 26621715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 22568744 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 40
Study 22568744 — intervention group
Group type: COMPARATOR
Intervention: Minocycline microspheres (LDD)
Number of subjects: 40
Study 21570516 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest Pain Unit (CPU)
Number of subjects: 407
Study 21570516 — intervention group
Group type: COMPARATOR
Intervention: Admission to hospital
Number of subjects: 407
Study 21570516 — intervention group
Group type: EXPERIMENTAL
Intervention: Admitted from CPU
Number of subjects: 407
Study 21570516 — intervention group
Group type: EXPERIMENTAL
Intervention: Admitted after cardiac stress test in CPU
Number of subjects: 407
Study 21570516 — intervention group
Group type: COMPARATOR
Intervention: Dismissed from CPU
Number of subjects: 407
Study 19303793 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG (ONCAB)
Number of subjects: 52
Study 19303793 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB)
Number of subjects: 52
Study 19303793 — intervention group
Group type: COMPARATOR
Intervention: Both ONCAB and OPCAB
Number of subjects: 52
Study 17387168 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based follow-up (n = 75)
Number of subjects: 150
Study 17387168 — intervention group
Group type: COMPARATOR
Intervention: Center-based follow-up (n = 75)
Number of subjects: 150
Study 15252908 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP (n=203)
Number of subjects: 400
Study 15252908 — intervention group
Group type: COMPARATOR
Intervention: Office BP (n=197)
Number of subjects: 400
Study 11465413 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion vehicle for lidocaine
Number of subjects: 8
Study 11465413 — intervention group
Group type: COMPARATOR
Intervention: O/W emulsion-based cream for lidocaine
Number of subjects: 8
Study 11465413 — intervention group
Group type: COMPARATOR
Intervention: Both active treatments (microemulsion and O/W emulsion)
Number of subjects: 8
Study 9611474 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival application of 25% metronidazole gel
Number of subjects: 13
Study 9611474 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival scaling
Number of subjects: 13
Study 9611474 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of scaling and metronidazole gel application
Number of subjects: 13
Study 9611474 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated quadrant)
Number of subjects: 13
Study 7834161 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (2.5 mg.kg‐1 body weight)
Number of subjects: 4
Study 7834161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (25 ml in 150 ml of grapefruit juice)
Number of subjects: 4
Study 7834161 — intervention group
Group type: COMPARATOR
Intervention: Placebo (grapefruit juice)
Number of subjects: 4
Study 3202091 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (3 mg RE or 10,000 IU daily for 4 months)
Number of subjects: 30
Study 3202091 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 4 months)
Number of subjects: 30
Study 3202091 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 30
Study 31944804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 40
Study 31944804 — intervention group
Group type: COMPARATOR
Intervention: Supportive listening
Number of subjects: 40
Study 29171002 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel
Number of subjects: 1748
Study 29171002 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of carbamazepine and oxcarbazepine/phenytoin
Number of subjects: 1748
Study 29171002 — intervention group
Group type: COMPARATOR
Intervention: CYP3A-inducing AEDs
Number of subjects: 1748
Study 27708114 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 624
Study 27708114 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-users)
Number of subjects: 624
Study 26208341 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 85
Study 26208341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 23860530 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (day 1, 125 mg; days 2 and 3, 80 mg) with dexamethasone (12 mg on day 1, 4 mg on days 2 and 3)
Number of subjects: 94
Study 23860530 — intervention group
Group type: COMPARATOR
Intervention: Placebo with dexamethasone (20 mg on day 1, 8 mg on days 2 and 3)
Number of subjects: 94
Study 23860530 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (day 1, 125 mg; days 2 and 3, 80 mg)
Number of subjects: 94
Study 23860530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 19952817 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) 0.3 g.kg body mass
Number of subjects: 8
Study 19952817 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (placebo; PL trial) 0.045 g.kg body mass
Number of subjects: 8
Study 18639418 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser treatment
Number of subjects: 98
Study 18639418 — intervention group
Group type: COMPARATOR
Intervention: Foam sclerotherapy
Number of subjects: 98
Study 18639418 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 98
Study 17026559 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon preparation on the day of colonoscopy (on-the-day group)
Number of subjects: 121
Study 17026559 — intervention group
Group type: COMPARATOR
Intervention: Colon preparation the night before colonoscopy (previous night group)
Number of subjects: 121
Study 12968982 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (F) 0.5 mg kg(‐1) intravenously
Number of subjects: 12
Study 12968982 — intervention group
Group type: COMPARATOR
Intervention: High-salt (HS) diet
Number of subjects: 12
Study 12968982 — intervention group
Group type: COMPARATOR
Intervention: Low-salt (LS) diet
Number of subjects: 12
Study 11469297 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta-percha points containing calcium hydroxide
Number of subjects: 120
Study 11469297 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous calcium hydroxide suspension
Number of subjects: 120
Study 9200808 — intervention group
Group type: EXPERIMENTAL
Intervention: Hobble restraint in the prone position
Number of subjects: 6
Study 9200808 — intervention group
Group type: COMPARATOR
Intervention: Hobble restraint in the upright position
Number of subjects: 6
Study 8258267 — intervention group
Group type: EXPERIMENTAL
Intervention: TUDCA (Taurodeoxycholic acid)
Number of subjects: 30
Study 8258267 — intervention group
Group type: COMPARATOR
Intervention: UDCA (Ursodeoxycholic acid)
Number of subjects: 30
Study 3979225 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 6
Study 3979225 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon 1-21
Number of subjects: 6
Study 3979225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29528960 — intervention group
Group type: EXPERIMENTAL
Intervention: Full depth with 50% 1RM load
Number of subjects: 19
Study 29528960 — intervention group
Group type: EXPERIMENTAL
Intervention: Full depth with 85% 1RM load
Number of subjects: 19
Study 30082719 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory streams structured in sets of 3 elements (tritones) during NREM sleep
Number of subjects: 0
Study 30082719 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory streams structured in statistical regularities during wake period
Number of subjects: 0
Study 30082719 — intervention group
Group type: COMPARATOR
Intervention: Auditory streams randomly organized during NREM sleep
Number of subjects: 0
Study 27310598 — intervention group
Group type: EXPERIMENTAL
Intervention: Unknown Loads (UL)
Number of subjects: 28
Study 27310598 — intervention group
Group type: COMPARATOR
Intervention: Known Loads (KL)
Number of subjects: 28
Study 24816938 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiautomated volumetry (SaV)
Number of subjects: 20
Study 24816938 — intervention group
Group type: COMPARATOR
Intervention: RECIST-based volumes
Number of subjects: 20
Study 24816938 — intervention group
Group type: EXPERIMENTAL
Intervention: SaV and WHO-based relative changes in tumour volume
Number of subjects: 20
Study 22286332 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week exercise program (n = 81)
Number of subjects: 160
Study 22286332 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 79)
Number of subjects: 160
Study 20623006 — intervention group
Group type: COMPARATOR
Intervention: Biometric assessment based on GDV technique (images without filter)
Number of subjects: 48
Study 20623006 — intervention group
Group type: COMPARATOR
Intervention: Biometric assessment based on GDV technique (images with filter)
Number of subjects: 48
Study 18388097 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (500 mg every 8 hours for 49 days)
Number of subjects: 49
Study 18388097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 16024973 — intervention group
Group type: EXPERIMENTAL
Intervention: G/A or A/A genotypes
Number of subjects: 237
Study 16024973 — intervention group
Group type: COMPARATOR
Intervention: G/G homozygotes
Number of subjects: 237
Study 16024973 — intervention group
Group type: EXPERIMENTAL
Intervention: G/A and A/A patients
Number of subjects: 237
Study 12694431 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel low abrasive air-polishing powder
Number of subjects: 27
Study 12694431 — intervention group
Group type: COMPARATOR
Intervention: Hand instruments (positive control)
Number of subjects: 27
Study 12694431 — intervention group
Group type: COMPARATOR
Intervention: Negative control (untreated teeth)
Number of subjects: 27
Study 10968308 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management services
Number of subjects: 6409
Study 10968308 — intervention group
Group type: EXPERIMENTAL
Intervention: Total payments for health care
Number of subjects: 6409
Study 8667274 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer luting cement (Ketac-Cem Maxicap)
Number of subjects: 60
Study 8667274 — intervention group
Group type: COMPARATOR
Intervention: Zinc phosphate luting cement
Number of subjects: 60
Study 1346082 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 100
Study 1346082 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 100
Study 1346082 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Number of subjects: 100
Study 3913379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 8
Study 3913379 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 5 mg
Number of subjects: 8
Study 3913379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol + Prazosin
Number of subjects: 8
Study 3913379 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine + Prazosin
Number of subjects: 8
Study 3913379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 8
Study 3913379 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 8
Study 3913379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol, Clonidine, Prazosin
Number of subjects: 8
Study 3913379 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin + Clonidine
Number of subjects: 8
Study 31246057 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused therapy for trauma
Number of subjects: 38
Study 31246057 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional processes as predictors
Number of subjects: 38
Study 31246057 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in primary adaptive emotions from early to late treatment sessions
Number of subjects: 38
Study 29901507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF) treatment
Number of subjects: 61
Study 29901507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 26457986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine-plus-cyclophosphamide (FC)
Number of subjects: 777
Study 26457986 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 777
Study 26457986 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine (not specified if alone or in combination)
Number of subjects: 777
Study 26457986 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy that induces a complete remission (CR)
Number of subjects: 777
Study 26457986 — intervention group
Group type: EXPERIMENTAL
Intervention: FC-based second-line therapy (including rituximab in 20%) or stem cell transplant
Number of subjects: 777
Study 24489762 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia-care mapping (DCM)
Number of subjects: 318
Study 24489762 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 318
Study 22158147 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (VAR) 10 mg on demand
Number of subjects: 20
Study 22158147 — intervention group
Group type: COMPARATOR
Intervention: Matched-placebo (PLB)
Number of subjects: 20
Study 20332288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for chronic pain
Number of subjects: 0
Study 18053943 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose, 3 mg (Group A)
Number of subjects: 44
Study 18053943 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose, 10 mg (Group B)
Number of subjects: 44
Study 18053943 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 44
Study 18053943 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 44
Study 16118370 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive school-based intervention
Number of subjects: 2744
Study 16118370 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 2744
Study 11448380 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative biopsy specimens analyzed by histopathologist 1
Number of subjects: 40
Study 11448380 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative biopsy specimens analyzed by histopathologist 2
Number of subjects: 40
Study 11448380 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of absence of esophageal mucosal inflammation with normalized pH monitoring
Number of subjects: 40
Study 9924468 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (eutectic mixture of local anaesthetic)
Number of subjects: 40
Study 9924468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40